

David Belada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4780471/publications.pdf>

Version: 2024-02-01

81
papers

3,772
citations

304743

22
h-index

133252

59
g-index

83
all docs

83
docs citations

83
times ranked

3917
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2011, 377, 42-51.	13.7	957
2	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
3	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Nonâ€“Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	1.6	388
4	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3529-3537.	1.6	333
5	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2815-2824.	1.6	173
6	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq0 0 0 rBT /Overlock 10 Tf	10.7	135
7	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
8	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
9	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2018, 19, 1449-1458.	10.7	93
10	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1530-1542.	10.7	91
11	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. <i>Blood</i> , 2013, 122, 509-509.	1.4	66
12	Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1668-1674.	1.3	59
13	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578.	1.3	36
14	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. <i>Lancet Haematology,the</i> , 2015, 2, e166-e174.	4.6	36
15	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2021, 35, 1500-1505.	7.2	29
16	Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. <i>Leukemia and Lymphoma</i> , 2014, 55, 802-810.	1.3	28
17	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020, 34, 522-532.	7.2	26
18	Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 1278-1282.	0.8	25

#	ARTICLE	IF	CITATIONS
19	Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. <i>Leukemia and Lymphoma</i> , 2016, 57, 2777-2783.	1.3	25
20	A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent. <i>PLoS ONE</i> , 2014, 9, e102594.	2.5	24
21	Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?. <i>Leukemia and Lymphoma</i> , 2015, 56, 2350-2356.	1.3	23
22	First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1961-1972.	1.8	23
23	Phase 2 study of piasclisib (INCB050465), a highly selective, next-generation PI3K $\hat{\nu}$ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). <i>Leukemia and Lymphoma</i> , 2021, 62, 368-376.	1.3	23
24	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	5.2	21
25	Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. <i>Haematologica</i> , 2022, 107, 1633-1642.	3.5	21
26	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017, 130, 824-824.	1.4	21
27	Venous thromboembolism in patients with chronic lymphocytic leukemia. <i>Thrombosis Research</i> , 2015, 136, 1082-1086.	1.7	19
28	Alternating $\langle \text{sc} \rangle \text{R} \langle \text{sc} \rangle$ CHOP and $\langle \text{sc} \rangle \text{R} \langle \text{sc} \rangle$ cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 110-115.	1.7	18
29	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). <i>British Journal of Haematology</i> , 2020, 188, 240-248.	2.5	17
30	Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study. <i>Blood</i> , 2018, 132, 2882-2882.	1.4	17
31	Pixantrone+rituximab versus gemcitabine+rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. <i>Future Oncology</i> , 2016, 12, 1759-1768.	2.4	16
32	Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. <i>Blood</i> , 2014, 124, 4670-4670.	1.4	16
33	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7506-7506.	1.6	16
34	Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy. <i>Leukemia Research</i> , 2010, 34, e232-e234.	0.8	15
35	Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator's Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study. <i>Blood</i> , 2014, 124, 626-626.	1.4	15
36	The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. <i>Annals of Hematology</i> , 2018, 97, 669-678.	1.8	14

#	ARTICLE	IF	CITATIONS
37	Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. <i>European Journal of Haematology</i> , 2022, 109, 162-165.	2.2	13
38	Prospective subgroup analyses of the randomized <scp>MCL</scp>â€002 (<scp>SPRINT</scp>) study: lenalidomide <i>versus</i> investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	2.5	10
39	Potential loss of prognostic significance of minimal residual disease assessment after Râ€CHOPâ€based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. <i>Hematological Oncology</i> , 2018, 36, 773-778.	1.7	10
40	Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 9.	2.7	9
41	Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. <i>Journal of Cancer</i> , 2019, 10, 5041-5048.	2.5	9
42	Lowâ€dose fludarabine and cyclophosphamide combined with rituximab in the firstâ€line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): longâ€term results of project Qâ€lite by the Czech CLL Study Group. <i>British Journal of Haematology</i> , 2021, 193, 769-778.	2.5	9
43	Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 421-427.	0.9	8
44	Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. <i>Leukemia and Lymphoma</i> , 2016, 57, 1094-1103.	1.3	8
45	Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. <i>Leukemia and Lymphoma</i> , 2017, 58, 601-613.	1.3	7
46	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry<sup></sup>. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	1.3	7
47	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). <i>Blood</i> , 2021, 138, 813-813.	1.4	7
48	Trimodality imaging of colonic lymphoma. <i>Endoscopy</i> , 2009, 41, E1-E2.	1.8	6
49	Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group. <i>Blood</i> , 2010, 116, 2466-2466.	1.4	6
50	Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7502-LBA7502.	1.6	6
51	Cutaneous natural killer (NK)â€cell lymphoma: nasal type with extensive facial destruction. <i>International Journal of Dermatology</i> , 2009, 48, 1338-1342.	1.0	5
52	<scp>S</scp>tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: <scp>A</scp>n exploratory analysis of the PRIMA cohort study. <i>American Journal of Hematology</i> , 2016, 91, 410-415.	4.1	5
53	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. <i>Neoplasma</i> , 2014, 62, 585-592.	1.6	4
54	Ten yearsâ€™ experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2013-2018.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Optimization of the therapeutic procedure during LDL-apheresis—a computerized model. <i>Transfusion and Apheresis Science</i> , 2005, 32, 149-156.	1.0	3
56	NK/T-cell lymphoma nasal type with an unusual clinical course. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2014, 80, 564.	0.6	3
57	The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 145-148.	2.5	3
58	The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. <i>Leukemia Research</i> , 2018, 73, 29-38.	0.8	3
59	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.	1.4	3
60	The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI). <i>Blood</i> , 2014, 124, 4425-4425.	1.4	3
61	Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 57-64.	1.3	2
62	Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project. <i>Blood</i> , 2010, 116, 2882-2882.	1.4	2
63	Population-Based Analysis of Elderly Patients (> 70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry. <i>Blood</i> , 2016, 128, 3000-3000.	1.4	2
64	B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7571-TPS7571.	1.6	2
65	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab. <i>Leukemia Research</i> , 2010, 34, e140-e141.	0.8	1
66	Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13421.	3.4	1
67	Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results. <i>Blood</i> , 2012, 120, 1632-1632.	1.4	1
68	Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database. <i>Blood</i> , 2013, 122, 4387-4387.	1.4	1
69	Refractory mantle cell lymphoma in elderly patient - case report. <i>Onkologie (Czech Republic)</i> , 2017, 11, 149-153.	0.1	1
70	Primary testicular lymphoma. <i>Vnitřní Lekarství</i> , 2017, 63, 415-422.	0.2	1
71	Tumorous neo-vascularization: a newly recognized endoscopic feature of intestinal non-Hodgkin lymphoma. <i>Endoscopy</i> , 2007, 39, E95-E95.	1.8	0
72	Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. <i>EJHaem</i> , 2020, 1, 170-180.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4629-4629.	1.4	0
74	Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.. <i>Blood</i> , 2012, 120, 2649-2649.	1.4	0
75	Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results. <i>Blood</i> , 2014, 124, 1720-1720.	1.4	0
76	Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. <i>Blood</i> , 2016, 128, 2978-2978.	1.4	0
77	Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy. <i>Blood</i> , 2016, 128, 1779-1779.	1.4	0
78	The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 5413-5413.	1.4	0
79	Emergence of a lymphoma imitating an infectious infiltration surrounding the infrarenal aorta after EVAR. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 531-534.	1.4	0
80	Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma—a single-center, retrospective study. <i>Acta Medica (Hradec Kralove)</i> , 2007, 50, 113-8.	0.5	0
81	Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, e19553-e19553.	1.6	0